MCAD Deficiency Therapy Possibility With Aide from Heptanote and Derivatives

The results of a study by Al-Walid Mohsen, UPMC-CHP, and colleagues, presented at the 2022 lecture series of the International Network for Fatty Acid Oxidation Research and Management (INFORM) provided results that C7 could be a potential treatment for individuals suffering from medium-chain acyl-CoA dehydrogenase (MCAD).

MCAD deficiency and LCFAOD are both types of fatty acid oxidation disorders. MCAD deficiency can be differentiated from LCFAODs based on in vitro fatty acid oxidation rate studies.

The full article can be found here.